AstraZeneca CFO Aradhana Sarin (L) and CEO Pascal Soriot at the company's investor day (Ayisha Sharma for Endpoints News)

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

CAM­BRIDGE, UK — Pas­cal So­ri­ot has set an am­bi­tious $80 bil­lion rev­enue tar­get for As­traZeneca by 2030. But he’s not stop­ping there. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.